Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
MWN-AI** Summary
Legend Biotech Corporation (NASDAQ: LEGN), a leader in cell therapy innovation, has officially opened its new state-of-the-art research and development facility in Philadelphia, Pennsylvania. Occupying a 31,000-square-foot site at 2300 Market Street, this facility aims to bolster the company's efforts in advancing CAR-T cell therapies for various oncology and immunology indications.
The facility features advanced laboratories and collaborative workspaces designed to foster innovation and speed up the development of next-generation cell therapies. Legend Biotech CEO Ying Huang expressed that this new center marks a critical milestone in the company’s growth, enabling it to attract top talent and collaborate with leading research institutions in a city recognized for its life sciences prowess.
This Philadelphia site enhances Legend's presence in the U.S., which includes over 1,400 employees. The new facility is expected to create around 55 full-time jobs, supplementing its existing R&D operations in Piscataway, New Jersey. Guowei Fang, the President of Research and Development at Legend Biotech, highlighted that the Philadelphia team will be essential in advancing the company's innovative therapy pipeline and collaborating within the vibrant local biotech ecosystem.
Local officials and members of the Philadelphia biotech community attended a ribbon-cutting ceremony to celebrate this significant addition to the city's life sciences sector. Dr. Rebecca L. Grant, representing the City of Philadelphia's Department of Commerce, acknowledged Legend Biotech's commitment to contributing to the advancement of cell and gene therapy innovation in the region. Meanwhile, Chris Molineaux, CEO of Life Sciences Pennsylvania, welcomed the firm as a valuable addition to the city’s thriving biotech landscape.
Overall, the new facility underscores Legend Biotech's ongoing commitment to pioneering transformative therapies, particularly in the realm of CAR-T cell treatments, which hold promise for millions of patients.
MWN-AI** Analysis
Legend Biotech Corporation (NASDAQ: LEGN) recently celebrated the opening of a new 31,000-square-foot research facility in Philadelphia, marking a significant expansion of its R&D capacities in the competitive cell therapy sector. This development reinforces Legend's strategic positioning as a leading innovator in CAR-T therapy, particularly for oncology and immunology applications.
This facility, located in a prime biotech hub, is designed to enhance collaboration with local research institutions, thereby fostering innovation. The addition of approximately 55 employees further exemplifies Legend's commitment to growing its workforce, which currently exceeds 1,400 in the U.S. The decision to expand in Philadelphia reflects broader trends in life sciences investments and positions Legend to leverage local talent and infrastructure.
Legend Biotech is already at the forefront of CAR-T innovation with its flagship product, CARVYKTI®, which has been administered to over 9,000 patients. As the largest standalone cell therapy company, its future growth prospects look strong, especially as it expands its pipeline of therapies beyond multiple myeloma.
Investors should consider several key factors. First, the successful establishment of this R&D facility could catalyze advancements and further collaborations that enhance the company's innovation pipeline. Additionally, with the growing emphasis on cell therapies and potential regulatory approvals on the horizon, enhancements in portfolio offerings may lead to increased market share and revenue growth.
Nevertheless, potential investors should remain vigilant regarding market volatility and the inherent risks involved in biotech investments, including clinical trial outcomes and regulatory hurdles. The forward-looking statements in the company’s announcements suggest a promising trajectory, but stakeholders must weigh these optimistic projections against the typical uncertainties of the biotechnology sector. Overall, current market conditions appear favorable for Legend Biotech, but careful monitoring of industry developments will be essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
The facility will support CAR-T R&D in potential oncology and immunology indications
A Media Snippet accompanying this announcement is available by clicking on this link.
SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ribbon cutting of its new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania.
Located at 2300 Market Street, the 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies. The site features cutting-edge laboratories and collaborative workspaces designed to foster innovation and accelerate research programs across Legend’s oncology and immunology portfolios.
“This new facility marks an exciting milestone for Legend Biotech as we continue to invest in our future and strengthen our leadership in cell therapy innovation,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are proud to officially open our doors in Philadelphia, a world-class hub for life sciences, where we can attract top-tier talent, collaborate with premier research institutions, and advance our mission to bring transformative therapies to patients.”
The Philadelphia R&D center expands Legend’s American presence, which includes over 1,400 employees in the United States. The site will employ approximately 55 full-time team members and complements Legend’s existing R&D presence in Piscataway, New Jersey. Headquartered in Somerset, N.J., Legend also has manufacturing activities in Raritan and Morris Plains, N.J.
“The opening of our new facility represents an exciting new chapter for our research organization,” said Guowei Fang, Ph.D., President of Research and Development at Legend Biotech. “Our Philadelphia team will play a critical role in advancing our sustainable pipeline of innovative cell therapies, while strengthening collaborations within one of the nation’s most dynamic biotech ecosystems.”
Local officials, academic partners, patient advocacy groups, and members of the Philadelphia biotech community gathered with Legend Biotech leadership to celebrate the ribbon-cutting ceremony and tour the new facility.
“Legend Biotech’s decision to expand its R&D footprint in Philadelphia reflects the strength and momentum of our city’s life sciences ecosystem,” said Dr. Rebecca L. Grant, Director of Life Sciences & Innovation for the City of Philadelphia’s Department of Commerce. “Philadelphia is home to world-class scientific talent and research institutions, and we are proud to welcome an organization committed to pioneering therapies that change patient lives. We look forward to supporting Legend Biotech as they grow here and contribute to the continued advancement of cell and gene therapy innovation in our city.”
“Philadelphia continues to be a magnet for innovation and scientific excellence,” said Chris Molineaux, CEO of Life Sciences Pennsylvania. “We are thrilled to welcome Legend Biotech to our city’s thriving life sciences community. Their investment brings high-quality jobs, research opportunities, and further reinforces Philadelphia’s growing reputation as a global leader in healthcare innovation.”
About Legend Biotech
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI ® , a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. To date, CARVYKTI has been administered to over 9,000 patients with multiple myeloma at 132 treatment centers spanning 44 states across the U.S. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on LinkedIn .
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 11, 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
media@legendbiotech.com
FAQ**
How does the expansion of Legend Biotech Corporation LEGN's R&D footprint in Philadelphia impact its competitive position in the cell therapy market compared to other biotech firms?
What specific oncology and immunology indications will the new facility focus on for CAR-T therapy development, and how does this align with Legend Biotech Corporation LEGN's existing pipeline?
Can you elaborate on the anticipated collaborations between Legend Biotech Corporation LEGN and local research institutions in Philadelphia to enhance their R&D initiatives?
With the employment of 55 full-time team members at the new site, how does Legend Biotech Corporation LEGN plan to attract top-tier talent to support its innovative cell therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Legend Biotech Corporation (NASDAQ: LEGN).
NASDAQ: LEGN
LEGN Trading
-0.16% G/L:
$34.565 Last:
2,223,613 Volume:
$34.975 Open:
